Search: onr:"swepub:oai:DiVA.org:uu-431895" >
Different patterns ...
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic) : A multinational observational study.
-
Persson, Frederik (author)
-
Bodegard, Johan (author)
-
Lahtela, Jorma T (author)
-
show more...
-
- Nyström, Thomas (author)
- Karolinska Institutet
-
Jørgensen, Marit E (author)
-
Jensen, Majken Linneman (author)
-
Gulseth, Hanne L (author)
-
Thuresson, Marcus (author)
-
Hoti, Fabian (author)
-
- Nathanson, David (author)
- Karolinska Institutet
-
- Norhammar, Anna (author)
- Karolinska Institutet
-
Birkeland, Kåre I (author)
-
Eriksson, Johan G (author)
-
- Eriksson, Jan (author)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
show less...
-
(creator_code:org_t)
- 2018-08-31
- 2018
- English.
-
In: Endocrinology, diabetes & metabolism. - : Wiley. - 2398-9238. ; 1:4
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Aims: The understanding of second-line use of glucose-lowering drugs (GLDs) in the general population with type 2 diabetes (T2D) treatment is important as recent results have shown cardiovascular benefits with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). Our aim was to describe second-line GLD treatment patterns in four Nordic countries.Methods: All T2D patients treated with GLD between 2006 and 2015 were identified in prescribed drug registries in Denmark, Finland, Norway and Sweden, and linked with National Patient and Cause of Death Registries. Second-line treatment was defined as a prescription of a second GLD class following ≥6 months of metformin monotherapy. Index was the date of first dispense of the second-line drug.Results: A rapid uptake of newer GLDs (GLP-1RA, DPP-4i and SGLT-2i) over the 10-year observation period was seen in Denmark, Finland and Norway, while slower in Sweden. In 2015, 33,880 (3.1%) of 1,078,692 T2D patients initiated second-line treatment, and newer GLDs were more commonly used in Finland (92%), Norway (71%) and Denmark (70%) vs Sweden (44%). In 2015, the use of older GLDs (insulin and sulphonylureas) was 7-fold greater in Sweden compared to Finland (49% vs 7%), and 1.6-fold greater compared with Denmark and Norway (49% vs 30% and 29%, respectively).Conclusions: Despite comparable demography and healthcare systems in four neighbouring countries, surprisingly large differences in second-line use of newer GLDs were found. With recent evidence of potential cardiovascular benefits with newer GLDs, such differences may have an important impact on cardiovascular outcomes.
Keyword
- SGLT2
- observational study
- second‐line
- type 2 diabetes
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Persson, Frederi ...
-
Bodegard, Johan
-
Lahtela, Jorma T
-
Nyström, Thomas
-
Jørgensen, Marit ...
-
Jensen, Majken L ...
-
show more...
-
Gulseth, Hanne L
-
Thuresson, Marcu ...
-
Hoti, Fabian
-
Nathanson, David
-
Norhammar, Anna
-
Birkeland, Kåre ...
-
Eriksson, Johan ...
-
Eriksson, Jan
-
show less...
- Articles in the publication
-
Endocrinology, d ...
- By the university
-
Uppsala University
-
Karolinska Institutet